On the Couch with Jon Pilcher (Neuren): DAYBUE, Europe and What Comes Next
In this episode of On the Couch, Henry Jennings speaks with Jon Pilcher, CEO of Neuren Pharmaceuticals (ASX: NEU), on his fourth appearance on the podcast. They cover the European regulatory setback, strong US sales momentum, and what the phase three trial for Neuren's second drug candidate means for the company's outlook. — Marcus Today – Daily Market Insights Marcus Today provides clear, practical commentary for self-directed investors – covering markets, portfolios, education, and decision...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from On the Couch
On the Couch with Dr Liz Dallimore (Argenica): Phase Two, FDA and What's Ahead
On the Couch with Nick Griffin (Munro Partners): Markets, AI and Global Tech Themes
Why the Next Six Months Could Get Tough for Small Caps: On the Couch with Chris Stott
On the Couch with Coby Hanoch (Weebit Nano): The Memory Boom Behind AI
Get summaries like this every morning.
Free AI-powered recaps of On the Couch and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.